patent.fyi
Applications  /  US 2026/0355150
United States Patent Application Publication

US 2026/0355150 A1

Published
Nov 12, 2026
Filed
Aug 29, 2023
Earliest date on the face
Aug 30, 2022
Classification
A61K 31/381
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Add a dopamine partial agonist

What ifWhat if the patient continues the antidepressant and adds an oral dopamine D2 receptor partial agonist?
Claim language“ulotaront or a pharmaceutically acceptable salt thereof”

The prescriber adds aripiprazole to the ongoing antidepressant regimen. Follow-up visits track depressive symptoms and assess restlessness and other movement symptoms during dose adjustment.

1.1Add magnetic stimulation sessions

What ifWhat if the patient continues the antidepressant and receives repetitive transcranial magnetic stimulation as the adjunct?
Claim language“ulotaront or a pharmaceutically acceptable salt thereof”

A figure-eight coil delivers repeated magnetic pulses over the left dorsolateral prefrontal cortex. The operator sets pulse intensity relative to the patient's motor threshold and repeats sessions on a scheduled course.

1.1Add structured cognitive therapy

What ifWhat if the patient continues the antidepressant and adds individual cognitive behavioral therapy?
Claim language“ulotaront or a pharmaceutically acceptable salt thereof”

The therapist and patient use activity schedules and thought records to identify patterns associated with depressed mood. Between sessions, the patient carries out planned activities and records changes in mood and daily functioning.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Adjunctive treatment in a day hospital

A psychiatric day hospital enrolls adults with major depressive disorder whose symptoms persist despite antidepressant treatment. Participants continue their prescribed antidepressant and receive adjunctive ulotaront under a research protocol. Nursing staff record doses taken during program hours and reconcile home doses at the next visit.

Component substitution

Bupropion as the background antidepressant

A research protocol uses bupropion as the background antidepressant for adults with major depressive disorder who show an inadequate response to an adequate course of bupropion. The protocol adds ulotaront as a separate oral medication and keeps the established bupropion dose fixed during the assessment period unless a clinician changes treatment. The study record tracks administration, depressive symptoms, and adverse events for each participant.

Parameter or scale variation

Symptom tracking with two baseline measurements

Adults with an inadequate antidepressant response continue their antidepressant when adjunctive ulotaront begins. Participants complete a nine-item depression questionnaire 7 days before the first adjunctive dose and again immediately before that dose on day 0. They repeat the questionnaire on days 7, 14, and 28, and the study software calculates each follow-up score's change from the mean of the two baseline scores.

Combination with existing systems

Dose capture through electronic medication records

A supervised treatment unit enters the ongoing antidepressant and adjunctive ulotaront as separate orders in its electronic medication administration record. A nurse scans the participant's wristband and each unit-dose package at administration. The record links the administration time and dose status to the corresponding order and records a reason for each missed dose.

Automated or data-driven variant

Electronic screening from longitudinal symptom scores

Screening software retrieves antidepressant orders, documented dose changes, and dated depression questionnaire scores from the electronic health record. It pairs pretreatment and follow-up scores from the same questionnaire and flags records that meet the research protocol's requirements for treatment duration and persistent symptoms. A clinician verifies medication exposure and symptom history before confirming eligibility for adjunctive ulotaront alongside the ongoing antidepressant.

Medication adherence tracking with electronic caps

Each participant receives separate bottles with electronic caps for the background antidepressant and adjunctive ulotaront. The caps log opening times, and a participant diary records dose times and doses removed in advance. Study software aligns both data sources with scheduled dose times and flags discrepancies for staff review.

Specific version of a part

Separate immediate release tablets

The patient takes the ongoing antidepressant tablet and a separate immediate-release tablet containing ulotaront. Separate dosage units allow adjustment of the ulotaront dose while the antidepressant dose stays fixed.

Encapsulated ulotaront salt formulation

A hard capsule contains a measured quantity of a pharmaceutically acceptable ulotaront salt blended with microcrystalline cellulose. The capsule strength is expressed as the mass of ulotaront it provides, and the patient takes the antidepressant in a separate dosage unit.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2013/0236573 A1
Published
Sep 12, 2013
Filed
Mar 12, 2013
Class
A61K 31/135
Document BUS 2019/0099393 A1
Published
Apr 4, 2019
Filed
Sep 12, 2018
Class
A61K 31/215
Claim 1
Document A
Document B
1.1administering the antidepressant therapy and a therapeutically effective amount of ulotaront or a pharmaceutically acceptable salt thereof to the subject.
The present invention is further directed to a method for the treatment of treatment-refractory or treatment-resistant depression (TRD) comprising administering to a patient in need thereof, combination therapy with a therapeutically effective amount of esketamine and at least one antidepressant, as herein defined.
A · US 2013/0236573 A1 · ¶ 14
A method for treating therapy refractory depression, comprising co-administering an inhibitor of 11-beta-HSD-2 or metabolites thereof with an antidepressant drug.
B · US 2019/0099393 A1 · claim 20

An empty cell means only that no passage was reproduced there.

Statements in these documents
Moreover, about approximately 30% of depressed patients remain partially or totally treatment-resistant to at least two antidepressant treatments including combination treatments.
A · US 2013/0236573 A1 · ¶ 5
The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a therapeutically effective amount of esketamine as mono-therapy or as combination therapy with at least one antidepressant.
A · US 2013/0236573 A1 · ¶ 2
Therefore, there is a need to identify patients, which do not respond to currently used antidepressants as early as possible and apply a differentiated treatment strategy.
B · US 2019/0099393 A1 · ¶ 7
Another embodiment of the method combines the described compounds with forms of Magnesium salts in order to overcome longer term tolerability issues with the compounds, which are in the center of the invention.
B · US 2019/0099393 A1 · ¶ 6
Cite aspatent.fyi, US 2026/0355150 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355150/, SHA-256 30082790c220d6849aca3f51de1e472ea4601015a14efbf6f96e61c1ec1d3c8c
First published
Permanent addresshttps://patent.fyi/US20260355150/
Content fingerprint (SHA-256)30082790c220d6849aca3f51de1e472ea4601015a14efbf6f96e61c1ec1d3c8c
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi